This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
About Sino Biological Sino Biological is an international reagent supplier and contract research service provider. The company specialises in recombinant proteinproduction and antibody development. We are pleased to welcome them to Houston.”
We will leverage this financing to accelerate collaborative research with pharmaceutical manufacturers and internal research using its own pipeline. Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using proteinproduction technology such as enzymes cultivated by our technology.
million liters in 2021, according to an analysis by BioProcess International. market with Wegovy will, by 2030, require about one million liters of production capacity. In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease.
Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapyproducts, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?
This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. 3/ Cell Membrane Editor A cell is a lipid shell with lots of DNA, proteins, and RNA molecules inside. Molecular Therapy. Read Novartis bought a blood stem cell gene therapy program for $87.5
This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. 3/ Cell Membrane Editor A cell is a lipid shell with lots of DNA, proteins, and RNA molecules inside. Molecular Therapy. Read Novartis bought a blood stem cell gene therapy program for $87.5
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content